Sorrento Therapeutics Inc

NASDAQ:SRNE  
6.62
+0.27 (+4.25%)
Products, Regulatory, Other Pre-Announcement

Sorrento Therapeutics Releases Positive Results Of Phase 1B Trial Of Resiniferatoxin Epidural

Published: 09/22/2020 18:36 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Therapeutics Releases Positive Results of Phase 1b Trial of Resiniferatoxin (rtx) Epidural in Cancer Patients With Reported Intractable Pain.
Sorrento Therapeutics Inc - No Dose Limiting Toxicities Were Reported.
Sorrento Therapeutics Inc - Expects to Submit to FDA a Request to Proceed With a Phase 3 Clinical Trial in Orphan Indication Imminently.